Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Clinical Trial ID NCT01518413

PubWeight™ 6.49‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01518413

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol 2013 0.95
2 Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy. Paediatr Drugs 2015 0.86
3 Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma. Int J Mol Sci 2016 0.82
4 Bone sarcomas: from biology to targeted therapies. Sarcoma 2012 0.82
5 Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int 2016 0.81
6 Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev 2015 0.81
7 Advances in paediatric cancer treatment. Transl Pediatr 2014 0.76
8 Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer 2015 0.76
Next 100